Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (43)COVID-19 (36)

Type

TypeGuidance (3883)Indicators (267)News (230)NICE advice (496)Quality standards (255)Research recommendations (1922)

Status

StatusAwaiting development (327)Discontinued (382)In consultation (6)In development (423)Published (2460)Topic selection (289)

Last updated

Last updatedLast 3 months (60)Last 6 months (142)Last year (584)Last 3 years (1773)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (25)Cancer service guidelines (10)Clinical guidelines (380)COVID-19 NHSE/I specialty guides (2)COVID-19 rapid guidelines (27)Diagnostics guidance (93)Health technology evaluations (38)Highly specialised technologies guidance (47)Interventional procedures guidance (950)Medical technologies guidance (154)Medicines practice guidelines (5)NICE guidelines (562)Public health guidelines (88)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2035)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)

Showing 6706 to 6720 of 7680 results

Sort by

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued [GID-TA10212]
Result type
Technology appraisal guidance
Status
Discontinued
Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]
Discontinued [GID-TA10045]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued [GID-TA10321]
Result type
Technology appraisal guidance
Status
Discontinued
Alzheimer's disease (early) - gantenerumab [ID6142]
In development [GID-TA11269] Expected publication date: TBC
Result type
Technology appraisal guidance
Status
In development
Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
Discontinued [GID-TA10277]
Result type
Technology appraisal guidance
Status
Discontinued
Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]
Discontinued [GID-TAG444]
Result type
Technology appraisal guidance
Status
Discontinued
Faller's clinics for the assessment and prevention of falls [ID103]
Discontinued [GID-TAG375]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued [GID-TA10193]
Result type
Technology appraisal guidance
Status
Discontinued
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued [GID-TAG399]
Result type
Technology appraisal guidance
Status
Discontinued
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
Discontinued [GID-TA10353]
Result type
Technology appraisal guidance
Status
Discontinued
Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]
Discontinued [GID-TAG407]
Result type
Technology appraisal guidance
Status
Discontinued
Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]
Discontinued [GID-TA10318]
Result type
Technology appraisal guidance
Status
Discontinued
Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]
Discontinued [GID-TA10171]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]
Discontinued [GID-TA10110]
Result type
Technology appraisal guidance
Status
Discontinued
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]
Discontinued [GID-TAG360]
Result type
Technology appraisal guidance
Status
Discontinued

Previous page
1
…
446
447
Current page 448
449
450
…
512
Page 448 of 512
Next page

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Knowledge resources

About NICE
Into practice
Get involved with NICE
Jobs
News
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2024. All rights reserved. Subject to Notice of rights.